Search results for: Pricing and Reimbursement
Filter search results
Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
11 July 2023
…and medicine research and development (R&D) is significantly lower in comparison to other diseases such as cancer. However, recent breakthroughs and growing R&D pipeline show that this area has high…
The value of fast diagnostics in time-critical infections
20 April 2026
…Japan, the United Kingdom, and the United States) and incorporates expert‑validated clinical inputs, country‑specific cost data, and conservative assumptions. The findings show meaningful health gains, substantial cost savings, and consistent…
From STEDI to STRIDES: Valuing broader health-system benefits of AMR diagnostics
21 July 2025
…economies worldwide. To this end, key priorities include prevention and infectious disease management, increasing uptake and access to treatment and diagnoses and overall improved antimicrobial stewardship. The evolving understanding of…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…the beginning of his acceptance speech, Professor Hollis invited us to consider innovative drug pricing and reimbursement with a fishing analogy. There are multiple strategies for catching fish, for example,…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…and pricing and reimbursement—to support a resilient healthcare and innovation ecosystem for rare diseases. Promoting equitable access to medicines for rare diseases is a key component of the World Health…
Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA
9 June 2025
…included in evaluations and decision-making processes. Impact on pricing: It is unclear whether and how ANEFiTS would influence the pricing of new health technologies, a critical element for ensuring affordability and…
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
…pharmaceutical research and development and biopharmaceutical innovation. In this blog we discuss is detail why the assumptions in the CBO’s model are too uncertain to be useful for policymakers. A…
Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
11 April 2023
…can lead to substantively different results and recommendations that could undermine access to new technologies that could improve patient and carer outcomes. To address these challenges, and appropriately value the…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries. There is considerable variation in the degree and…